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Sensitive tools are needed to accurately establish the diagnosis of tuberculosis (TB) at 
death, especially in low-income countries. The objective of this study was to evaluate 
the burden of TB in a series of patients who died in a tertiary referral hospital in sub-
Saharan Africa using an in-house real time PCR (TB-PCR) and the Xpert MTB/RIF 
Ultra (Xpert Ultra) assay. 
Complete diagnostic autopsies were performed in a series of 223 deaths (56.5% being 
HIV-positive), including 54 children, 57 maternal deaths and 112 other adults occurring 
at the Maputo Central Hospital, Mozambique. TB-PCR was performed in all lung, 
cerebrospinal fluid and central nervous system samples in HIV-positive patients. All 
samples positive for TB-PCR or showing histological findings suggestive of TB were 
analysed with the Xpert Ultra assay. 
TB was identified as the cause of death in 31 patients: 3/54 (6%) children, 5/57 (9%) 
maternal deaths and 23/112 (21%) other adults. The sensitivity of the main clinical 
diagnosis to detect TB as the cause of death was 19.4% (95% CI: 7.5-37.5) and the 
specificity was 97.4% (94.0-99.1) compared to autopsy findings. Concomitant TB (TB 
disease in a patient dying of other causes) was found in 31 additional cases. Xpert 
Ultra helped to identify 15 cases of concomitant TB. In 18 patients, M. tuberculosis 
DNA was identified by TB-PCR and Xpert Ultra in the absence of histological TB 
lesions. Overall, 62 cases (27.8%) had TB disease at death and 80 (35.9%) had TB 
findings. 
The use of highly sensitive, easy to perform molecular tests in complete diagnostic 
autopsies may contribute to identifying TB cases at death that would have otherwise 
been missed. Routine use of these tools in certain diagnostic algorithms for 
hospitalised patients needs to be considered. Clinical diagnosis showed poor sensitivity 
for the diagnosis of TB at death. 
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Introduction  
Tuberculosis (TB) remains a major public health concern in most countries of the world. 
In 2017, the World Health Organization (WHO) estimated around 10 million new cases 
and 1.6 million deaths attributable to TB.1 As a single cause of death (CoD), TB is the 
main infectious killer at a global level. It is also the most frequent cause of HIV-
associated deaths2, and ranks among the principal CoD among women of reproductive 
age3–5. Similar to other countries in the region, the HIV and TB epidemic in 
Mozambique is devastating.1,6 The estimated national incidence rate of TB in 2017 was 
551 per 100,000 inhabitants with a case fatality ratio of 31% (around 49,000 deaths in 
2017) and HIV coinfection rate among new TB cases of 40%.1  
Accurate and reliable TB mortality data are fundamental to improve patient 
management, prioritize public health interventions and assess progress in the WHO 
End TB strategy indicators7. Despite the enormous TB burden, there is considerable 
uncertainty as to the actual mortality attributable to this disease, especially in  some 
low-income countries (LICs) with high disease burden.8 Mortality estimates based on 
case fatality rates reported by national TB programmes are of low quality.9 Clinical 
diagnosis and verbal autopsies have limited sensitivity and specificity for diagnosing TB 
as the CoD compared to complete diagnostic autopsy (CDA), the current gold 
standard2,9–13. Studies assessing clinico-pathological discrepancies have shown a high 
degree of misclassification when assigning deaths to TB in either direction (clinically 
missed TB causing death and false attribution of TB as the CoD when not present).10,11  
Additionally, most of the TB disease identified in CDA studies is considered as 
responsible for the death of the patients2. The diagnosis of TB disease in these studies 
is based on obvious macroscopic disease, confirmed microscopically by the presence 
of granulomas with Ziehl-Neelsen stain-positive bacilli. However, it is likely that earlier 
forms of TB, in which pathological findings might not be that obvious, are missed. 
When there are other plausible causes of death and concomitant TB disease, the exact 
role that TB might have played in the chain of events leading to death may not be clear. 
This can be especially true in immunocompromised HIV-positive patients.14  
As part of a large post-mortem study conducted at a tertiary referral hospital in 
Mozambique 15–18 two molecular tests were used to diagnose TB, an in house real time 
PCR and the Xpert MTB/RIF Ultra assay (Xpert Ultra). The study had two main 
objectives: 1) to describe the overall burden of TB as the CoD and as a concomitant 
finding (TB disease identified at death, but not directly causing death), and 2) to assess 
the proportion of clinically missed TB cases. 
Methods 
Study design 
This was an ancillary study to a prospective observational postmortem evaluation 
aimed at validating minimally invasive autopsy for CoD determination in different age 
groups compared withCDA, the gold standard technique.19 This study included 
childhood (≥ 1 months to 15 years old), adult, and maternal deaths (the latter defined 
as deaths among women while pregnant or within 42 days of termination of 
pregnancy). Traumatic deaths were excluded.20 The study was conducted from 
November 2013 to March 2015 at the Department of Pathology of the Maputo Central 
Hospital, a 1500-bed government-funded tertiary health care centre, in collaboration 
with the departments of paediatrics, internal medicine and obstetrics and gynaecology. 
Prior informed consent was obtained from the relatives of the deceased. The study 
received approval from the Clinical Research Ethics Committee of the Hospital Clinic of 
Barcelona (Spain; File 2013/8677) and the National Bioethics Committee of 
Mozambique (Mozambique; Ref. 342/CNBS/13).  
The pathological and microbiological methods of the CDA procedures have been 
described elsewhere.21,22, Samples were obtained from all organs for histological and 
microbiological analysis. Samples for microbiological testing were collected in nucleic-
acid preserving buffer (ATL lysis buffer, Qiagen). Clinical information was collected 
from each patient using a standardized questionnaire after thorough revision of the 
entire medical record. The data obtained included demographic data, past medical 
history, as well as information about the inpatient admission process, signs and 
symptoms, physical examination, laboratory and imaging results when available, and 
treatment received during hospitalisation. For maternal deaths, the obstetric history 
was also reviewed. Following analyses of the CDA samples, a panel composed of a 
pathologist, a microbiologist and a clinician (paediatrician, internist or gynaecologist, 
depending on the age group) evaluated the pathological and microbiological reports of 
the CDA and the clinical data and assigned the CDA diagnosis of CoD. The main 
results of this validation project have been published.15–18 
HIV status was confirmed postmortem by an automated method detecting antibodies 
against HIV (ADVIA Centaur HIV 1/0/2 Enhanced assay, Siemens Healthcare 
Diagnostics) and by viral load testing using the Cobas TaqMan HIV-1 test v2.0 (Roche 
Molecular Systems). 
TB testing strategy and laboratory procedures 
The TB testing strategy of the study is summarized in Figure 1. The initial 
microbiological diagnosis of TB was performed using an in-house real-time PCR 
targeting M. tuberculosis (TB-PCR). TB-PCR was performed in all lung samples 
obtained at CDA, independently of the presence or absence of histological lesions, and 
in any other organ showing histological lesions suggestive of TB (granulomatous 
inflammatory reaction and/or caseous necrosis). In addition, in HIV positive patients, 
TB was routinely tested by TB-PCR in all CNS and CSF samples (independently of the 
presence or absence of lesions). Histological testing for TB included Ziehl-Neelsen 
staining when TB was suspected on the hematoxylin-eosin (H&E) stained slides.  
In addition, the Xpert MTB/RIF Ultra assay (hereinafter Xpert Ultra) was performed in: 
a) any organ with histological lesions suggestive or compatible with TB and positive 
TB-PCR (cases with TB disease), and b) in all deaths in which there was 
microbiological-histological discordance (histological lesions suggestive of TB with 
negative TB-PCR or positive TB-PCR without histological lesions suggestive of TB).  
Tissue samples for Xpert Ultra were thawed and homogenized using a handheld rotor-
stator homogenizer (Qiagen) in ATL lysis buffer (Qiagen). One-hundred µL of the 
homogenized tissue sample were added to 300 µL of saline solution. The resulting 400 
µL of sample were mixed with 1600 µL of Xpert Ultra Sample Reagent and then loaded 
into the cartridge. In house TB-PCR was performed using the procedures described by 
Espasa et al.23 
 
Definitions of TB associated findings 
“Histological lesions suggestive of TB” were defined as granulomatous inflammatory 
reactions with or without caseous necrosis, independently of the presence or absence 
of visible acid-fast bacilli on Ziehl-Neelsen staining. “Histological lesions compatible 
with TB” included non-specific inflammatory reactions (such as neutrophilic 
inflammation) which have been described in TB.24  
“TB disease at death” included histological lesions suggestive of TB with a positive TB-
PCR or a positive Xpert Ultra in any sample or when there were TB-compatible 
histological lesions and both TB-PCR and Xpert Ultra were positive. TB disease at 
death was further classified as “TB as CoD” when the review of the entire CDA 
(including histological, microbiological and clinical data) following a previously 
described algorithm of CoD determination, deemed TB to be the CoD, 25 which 
corresponds to the “-a diagnosis” in the WHO international form of medical certificate of 
death.26 A case was classified as “concomitant TB” when histological lesions 
compatible with TB were present at death but the review of the CDA deemed another 
disease as the most likely CoD (“-b”, “-c diagnoses”, or “other significant conditions” in 
the WHO international form of medical certificate of death). Finally, a case was 
classified as “M. tuberculosis DNA detection” when both TB-PCR and Xpert Ultra were 
positive in the absence of compatible histological findings. A single positive TB-PCR 
without any histological finding compatible with TB was considered a false positive 
result, since sample contamination or a true false positive result due to assay- or 
human-related performance could not be ruled out.  
Statistical analysis 
All the clinical data and the results of the histopathological and microbiological 
examination of the samples were analysed using Stata 13 (Stata Corp., College 
Station, TX). We calculated the proportions of: a) cases in which TB was the CoD; b) 
cases with concomitant TB; and c) cases with M. tuberculosis DNA. We estimated the 
sensitivity, specificity and predictive values of the clinical diagnoses to detect TB 
disease as the CoD (when the clinician specified TB as the main diagnosis as well as 
to detect concomitant TB (when the clinician specified TB among the diagnoses or 
initiated anti-TB treatment), using CDA diagnoses as the gold standard. 
Results 
The analysis included 223 deaths: 54 children, 57 maternal deaths and 112 other 
adults. HIV infection was identified in 32.7% (17/52), 65.2% (36/57) and 63.2% 
(73/112) of these deaths, respectively (56.5% of the overall series).  
Tuberculosis-associated findings 
TB was diagnosed as the CoD in 31 patients: 3/54 children (5.6%, 95% confidence 
interval [CI]: 1.2-15.4), 5/57 maternal deaths (8.8%, 95% CI: 2.9-19.3), and 23/112 
other adults (20.5%, 95% CI: 13.5-29.2). Among HIV-positive cases, TB was identified 
as the CoD in 0/17 (0%) children, 3/34 (8.8%, 95% CI: 1.9-23-7) maternal deaths, and 
18/73 (24.6%, 95% CI: 15.3-36.1) other adults. The most frequent form of TB as the 
CoD was miliary TB, (23/31; 74.2%), followed by pulmonary TB (6/31; 19.4%) and TB 
meningitis (2/31; 6.5%) (table 1). Among the 31 patients dying of TB, Xpert Ultra tested 
positive in all lung samples and 14 CSF samples.Concomitant TB was identified in 31 
additional patients: 8/54 children (14.8%), 18/112 adults (13.9%) and 5/57 maternal 
deaths (8.8%). Of these, 22 had pulmonary TB, 5 disseminated TB (more than 1 organ 
involved) and 4 had extrapulmonary TB involving a single organ (1 case with splenic 
TB, 3 with TB meningitis). Table 2 and figure 2 show the CoD of the cases with 
concomitant TB. Initially, 15 of 31 (48.4%) cases of concomitant TB disease did not 
have histological lesions suggestive of TB. Only after Xpert Ultra results were available 
(which prompted further histological review) the histological findings were deemed as 
TB compatible lesions (mostly inflammatory lesions).  
Eighteen additional cases fulfilled the definition of “M. tuberculosis DNA detection”: 
3/54 (6.6%) children, 5/57 (8.6%) maternal deaths and 10/112 (8.9%) adults. Of these 
cases, six died of an infectious cause and 12 of non-infectious conditions. Of the 18 
cases in which only M tuberculosis DNA was detected, six (33.3%) were HIV positive, 
and one (5.6%) had a history of past TB. 
Overall, TB findings were confirmed in 80 cases: 14/54 children (25.9%), 15/57 (26.3%) 
maternal deaths and 51/112 (45.5%) other adults. Among HIV positive patients, TB 
was confirmed in 3/17 (17.6%), 14/36 (38.9%) and 37/74 (50.7%) of patients in each 
study group, respectively (Table 1). Rifampicin resistance was detected by Xpert Ultra 
in eight cases. 
 
Clinical characteristics of patients with TB findings 
A clinical history of TB was reported in none of the children, in 2 (3.5%) maternal 
deaths and in 16 (14.3%) adults.  Twenty of 31 (65%) patients with TB as the CoD had 
reported cough compared to nine of 31 (29%) among those with concomitant TB at 
death (p=0.005). Among patients with TB findings, 8 cases were on antiTB treatment 
prior to admission, and in 10 antiTB treatment was initiated during admission. No 
differences were observed in terms of fever at admission, between patients with TB as 
the CoD and those with concomitant TB (17/31, 55%; vs. 19/31, 61%, p=0.6). The 
characteristics of cases with TB disease as the CoD, with concomitant TB, with M. 
tuberculosis DNA detection and those without any TB finding are shown in table 3.  
Clinico-pathological discrepancies 
Assuming that the first (main) clinical diagnosis was the CoD for clinicians, they had 
considered TB disease as the CoD in 11 of the 223 (4.9%) patients). However, the 
clinical diagnosis of TB as the CoD was correct in only 6 patients (figure 2).  Thus, the 
main clinical diagnosis had a sensitivity to detect TB disease as CoD of 19.4% (6/31, 
95% CI: 7.5-37.5) and a specificity of 97.4% (95% CI: 94.0-99.1) (table 4). Among the 
six cases in which clinicians correctly specified TB as the main clinical diagnosis, 
complete agreement with the form or localisation was only confirmed in two cases of 
pulmonary TB. Four patients showing miliary TB in the CDA were diagnosed as 
pulmonary TB or TB meningitis (3 and 1 patient respectively).  
Clinicians specified tuberculosis as one of the diagnoses at death (or initiated TB 
treatment) in 36 cases. However, only 20 cases were correctly diagnosed. The 
sensitivity of the clinical diagnosis (including decision to treat TB) for diagnosing TB 
disease at death (regardless of whether it was the CoD or concomitant TB) was 32.3% 
(20/62, 95% CI: 20.9 - 45.3) with a specificity of 90.1% (95% CI: 84.1-94.2). Thus, TB 
disease at death remained undiagnosed in 68% (42/62) of cases. By study group, the 
sensitivity of any clinical diagnosis to detect TB disease at death was 27.3% (3/11) in 
children, 24.4% (10/41) in adults and 10.0% (2/10) in maternal deaths (table 4). 
  
Discussion 
This study, which is part of one of the largest autopsy studies conducted in sub-
Saharan Africa, demonstrates the enormous burden of tuberculosis among children 
and adults, including maternal deaths, dying in a reference hospital in Mozambique. An 
even higher burden was found among HIV-positive adults and maternal deaths, in 
whom the proportion of TB findings rose up to 51% and 39% respectively. Importantly, 
it also shows alarming proportions of TB disease missed by clinicians and highlights 
the limitations of clinical diagnosis for ascertaining TB in resource constrained settings. 
In addition, the use of molecular assays (this is the first time Xpert Ultra has been used 
in a postmortem study)  allowed  M. tuberculosis to be detected in 8% (18/223) of 
patients in whom no histological changes were identified, possibly reflecting early forms 
of TB. This indicates that the total burden of TB at death might be even higher than 
what has been reported in clinical and epidemiological and even in many autopsy 
studies.  
A high burden of TB has also been found in some autopsy studies in countries 
neighbouring Mozambique, also within the context of high HIV and TB burden. In 
Zambia 65% of deaths in hospitalised patients >16 years of age (81% HIV-positive) 
were due to TB and in Kwazulu Natal, South Africa, 50% of adult inpatient deaths aged 
20-45 years had culture-confirmed TB (96% HIV-positive).10,27 A meta-analysis of 
autopsy studies showed that the prevalence of TB among HIV-positive adult deaths in 
sub-Saharan Africa was 43.2% (95% CI 38.0– 48.3%).2 We found a slightly lower 
percentage of cases in which TB was the CoD, perhaps because of different HIV 
treatment status, or because in some cases TB findings were not deemed as the most 
likely CoD. In fact, in their metaanalysis Gupta el al,  reported that in 91.4% (95% CI: 
85.8–97.0%) of cases in which TB was present at death it was also the primary CoD. 
Interestingly, we found that TB was the CoD in 50% of cases in which TB disease was 
present at death. This considerable proportion of TB disease not causing death can 
largely be explained by the additional cases with concomitant TB that were captured by 
a detailed pathological evaluation and the use of TB-PCR and Xpert Ultra in the 
diagnostic algorithm, and which might have been missed in other studies using 
traditional diagnostic tools.  
Additionally, in 18 cases with no histological evidence of TB, M. tuberculosis DNA was 
detected by two different molecular methods. These findings make the classification of 
this form of TB especially difficult, since the postmortem diagnosis of TB is not based 
on the diagnostic criteria used in living patients (sputum sample, presence of 
symptoms or chest radiography). It is unlikely that these findings correspond to 
contamination in the autopsy room, since disposable materials are used in each 
autopsy and the time that the tissue samples were exposed to potential airborne 
contamination is limited. Neither is it likely that these are false-positive cases, since 
DNA was detected by two different assays with different molecular targets. These 
findings may represent cases of incipient TB in which small histological lesions might 
be present but missed, since not all the tissue from all the organs was sampled for 
histological analysis.28 However,  these M. tuberculosis DNA findings may also 
represent the increasingly controversial concept of latent TB infection. Although it has 
been postulated that TB infection cannot be detected through direct diagnostic 
methods29, it has been suggested that it might be detected through detailed molecular 
studies in cases without histological evidence.30 It has also been suggested that there 
could be periods in the so-called latency or unstable infection period during which M. 
tuberculosis replicates at a higher rate, but this replication remains self-controlled.14 
The present study suggests and supports the idea of the existence of a spectrum of TB 
disease, ranging from early forms of TB in which  few bacilli are present (that might not 
necessarily develop into TB disease) to the traditional patent TB lesions (Figure 3). 
Clinical misclassification of TB was very frequent. In over 80% of TB identified as the 
CoD in CDA, the clinicians failed to identify TB as the event leading to death and 
overall, 67% of cases with TB disease at death were missed by the clinicians. 
Conversely, in 45% of the cases clinicians incorrectly established TB as the main 
cause of death or the presence of TB disease at death. The clinico-pathological 
discrepancies of TB disease at death have previously been reported and have 
implications for patient management as well as for estimating TB mortality burden.9,10 
Clinical diagnosis is not a good proxy of mortality by TB, and contrarily to what it was 
expected, it was poor in both HIV-positive and HIV-negative cases with TB disease. 
Thus, it is likely that the results of verbal autopsies are similarly bad or even worse as a 
tool to quantify TB mortality.12,13,31,32 Nonetheless, more studies comparing verbal 
autopsies with CDA are needed in order to demonstrate their usefulness as a tool for 
assessing TB?? mortality burden. It was of note that out of the 36 cases with TB 
findings in whom clinicians specified TB as a clinical diagnosis, only 18 were started on 
antiTB treatment (prior to or during admission). Possible reasons for this may be that 
when the patient died, clinicians might have reconsidered the potential diagnoses of 
the patient and then added TB, or that patients might have been too ill or died very 
early during admission. This which might have led to antiTB treatment not being 
initiated. Poor reporting of antiTB treatment initiation cannot be discarded. Ç 
Our study has several limitations. First, our conclusions can only be generalised to 
hospitalised patients of settings with similar epidemiological characteristics and do not 
necessarily represent the contribution of TB to all population-based mortality in Maputo 
or Mozambique. The likelihood of being hospitalised depends on access to healthcare, 
health infrastructure, severity of disease determined by healthcare workers and 
severity perceived by patients and relatives, among other sociological and behavioural 
factors. Likewise, diagnostic discrepancies might occur less frequently in larger 
hospitals, thus, those found in this study (carried out at the main reference hospital of 
the country) might underestimate the number of clinic-pathological discrepancies in 
general Mozambican health facilities. Second, as mentioned previously, all the organ 
samples were analysed histologically, but not all in their entirety, thus some cases of 
concomitant TB might have been missed. Third, TB culture was not contemplated in 
the study design, and this method could have helped to better characterise the 
microbiological findings. Likewise, the use of Xpert Ultra as a screening tool in all cases 
could have determined a higher number of confirmed cases and allowed estimation of 
the added yield of the use of this highly sensitive technology. Lastly, the quality of the 
clinical information may have been suboptimal in some cases of  hospitalised patients 
with severe disease status, and their degree of consciousness might have made some 
of the results prone to information bias. Thus, despite comprehensive evaluation of all 
the clinical records available, some relevant information about the medical history 
might have been missed by patients or relatives.  
In conclusion, we found a high burden of TB disease at death (as CoD and as 
concomitant disease) in all groups studied. The use of highly sensitive molecular tests 
in CDA helped to identify cases of TB disease at death that would have otherwise been 
missed. Indeed, the results demonstrate that in our setting, clinical diagnoses miss 
most of the TB disease which is detected in CDA. In addition, Xpert Ultra may have the 
potential to identify earlier forms of TB, before histological lesions are evident, or 
potentially, unstable latent TB infection.  
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Figure 1. Algorithm for determination of TB diagnosis used in samples from complete 
diagnostic autopsies.  
 
Figure 2. Alluvial diagram showing cause of death (CoD) as assigned in the complete 
diagnostic autopsy (CDA) and per clinical diagnosis whenever a TB diagnosis was 
involved. The left column shows all the TB diagnoses (as CoD) in CDA (31) as well as 
the associated CDA diagnoses when clinicians assigned TB as the CoD (5). The right 
column shows the clinical diagnoses of CoD when TB was specified by clinicians as 
well as the associated clinical diagnosis when the results of the CDA assigned TB as 
the CoD. 
 
Figure 3. Natural history of the TB model depending on bacillary burden and the 
likelihood of having immunological, microbiological, histological or radiological evidence 
at the time of death.  
 




Table 1. Number of patients with tuberculosis (TB) disease as the CoD, with concomitant TB disease and with M tuberculosis detection at death 
by study group and among HIV positive cases.  
1TB as Cause of death (CoD): when review of the entire CDA (including histological, microbiological and clinical data) following a previously 
described algorithm of CoD determination deemed TB to be the CoD, This definition required the presence of histological TB-compatible lesions 
and microbiological confirmation of TB by molecular assays. 
2Concomitant TB when histological lesions compatible with TB were present at death but review of the CDA deemed another disease as the 
most likely cause. This definition required the presence of histological TB-compatible lesions and microbiological confirmation of TB by 
molecular assays. 
3M. tuberculosis DNA detection was attributed when both TB-PCR and Xpert Ultra were positive in the absence of compatible histological 
findings. 
  
TB disease at death (compatible histology and confirmed with in-
house PCR and Xpert Ultra) 
  
  






M tuberculosis DNA 
detection
3 
Total cases with TB 
findings
4 
Study group Autopsies n % n % Total % n % #  % 
All autopsies            
Children 54 3 5.6 8 14.8 11 20.4 3 5.6 14 25.9 
Maternal Deaths 57 5 8.8 5 8.8 10 17.5 5 8.8 15 26.3 
Adults 112 23 20.5 18 16.1 41 36.6 10 8.9 51 45.5 
Total  223 31 13.9 31 13.9 62 27.8 18 8.1 80 35.9 
Autopsies among HIV positive cases*          
Children 17 0 0.0 3 17.6 3 17.6 0 0.0 3 17.6 
Maternal Deaths 36 5 13.9 4 11.1 9 25.0 5 13.9 14 38.9 
Adults 73 18 24.7 13 17.8 31 42.5 6 8.2 37  50.7 
Total  126 23 18.3 20 15.9 43 34.1 11 8.7 54 42.9 
4TB findings. In this column we include all cases in which TB disease was found at death (as the cause of death or as a concomitant finding) 
and cases in which only M. tuberculosis DNA were detected. 
*HIV status of two cases in children could not be ascertained. 
 
 









Type of TB (organs 
affected) 
1 Children Negative Rabies Rabies virus Pulmonary TB 













































Septic abortion Mycoplasma 
hominis 






















14 Other adults  negative Mucormycosis Rhizopus oryzae Extrapulmonary TB (CNS) 
15 












Other adults Positive 
Sepsis Streptococcus 
dysgalactiae Pulmonary TB 
18 
Other adults Positive 
Pneumonia Klebsiella 
pneumoniae 
Disseminated TB (liver 
lung) 
19 






Other adults Negative 
Meningitis Herpes simplex 
virus type 1 Pulmonary TB 
21 Other adults Positive Sepsis  Escherichia coli Pulmonary TB 
22 Other adults Negative Sepsis Candida glabrata Pulmonary TB 
23 







24 Other adults Negative Sepsis Enterobacter spp. Pulmonary TB 
25 
Other adults Positive 
Pneumonia Pseudomonas 
aeruginosa 
Disseminated TB (lung, 
CNS) 
26 
Other adults Positive 
Toxoplasmosis Toxoplasma gondii Disseminated TB (lung, 
liver, spleen) 













Disseminated TB (spleen, 
lung) 
30 



















Table 3. Characteristics of cases in whom the case of death was TB, with concomitant 
TB disease at death and with M. tuberculosis detection without histological evidence of 
TB. 
 




M tuberculosis DNA 
detection (n=18) 




Characteristics n (%)  n (%)  n (%)  n (%)  n (%) 
Sex 
   
  Male 13 (41.9) 20 (64.5) 7 (38.9) 55 (38.5) 95 (42.6) 
Female 18 (58.1) 2 (35.5) 11 (61.11) 88 (61.5) 128 (57.4) 
Study Group 
   
  Children 3 (9.7) 8 (25.8) 3 (16.7) 40 (28.0) 54 (24.2) 
Maternal 
deaths 
5 (16.1) 5 (16.1) 5 (27.8) 
42 (29.4) 57 (25.6) 




   
  Positive 23 (76.7)
#
 20 (64.5) 6 (35.3)
#
 71 (49.7) 95 (43.0) 
Negative 7 (23.3)
#
 11 (35.5) 11 (64.7)
#
 72 (50.3) 126 (57.0) 
History of TB 
   
  Yes  6 (19.4) 4 (12.9) 1 (5.6) 7 (4.9) 18 (8.1) 
No  25 (80.6) 27 (87.1) 17(94.4) 136 (95.1) 105 (91.9) 
On anti TB treatment prior toadmission 
 
  Yes  4 (13.3)* 4 (12.9) 0 (0.0)* 6 (4.4)* 14 (6.4) 
No  26 (86.7)* 27 (87.1) 17 (100)* 136 (95.6)*  206 (93.6) 
Reported fever at admission
&
 
  Yes  17( 54.8) 19 (61.3) 7 (38.9) 49 (35.5)
&
 92 (42.2) 
No  14(45.2) 12 (38.7) 11 (61.1) 89 (64.5)
&
 126 (57.8) 
Reported cough at admission
&
 
  Yes  20 (64.5) 9 (29.0) 2 (11.1) 28 (20.3)
&
 59 (27.1) 
No  11 (35.5) 22 (71.0) 16 (88.9) 110 (79.7)
&
  159 (72.9) 
 
* Information was not available in three cases. # HIV status could not be ascertained in 
two cases (one in the group who died of TB, and the other among those with M. 
tuberculosis detection. &Fever or cough was not recorded in 5 cases. M. tuberculosis 
detection included patients in whom M. tuberculosis DNA was detected without 
histological evidence of TB
Table 4. Diagnostic performance of clinical diagnosis* to determine: a) cause of death 
b) concomitant TB c) TB disease at death (TB as cause of death + concomitant TB). 
 
 TB as cause of 
death* 
Concomitant TB# TB disease at 
death 










(85.0 - 93.9) 90.06 87.0 - 95.4 
PPV 54.5 23.4-83.3 24 (9.4 - 45.1) 55.56 25.5 - 64.7 
NPV 88.2 83.1-92.2 87.
4 
(81.9 - 91.7) 77.54 81.7 - 91.6 
PPV: positive predictive value; NPV: negative predictive value 
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